MyMeds&Me Reportum® solution deployed by Pfizer Inc. for Pharmacovigilance in the U.S. market
London, UK, 9 March, 2015: MyMeds&Me, a leading SaaS provider of web-based adverse event and product quality complaint capture solutions for life sciences, today announced the deployment of the Reportum® solution across all Pfizer safety call centre sites for the U.S. market. This marks the signing of a hosting agreement with Pfizer to adopt the Reportum® solution via Software as a Service (SaaS) delivery. Pfizer has deployed the Reportum® solution from MyMeds&Me as the standard for the U.S. Safety Call Centre, to support prompt availability of high quality safety data from reporters, including consumers, patients and healthcare professionals.
Supporting Quotes:
“Improving processes with an easy to use electronic solution is key to maintaining high levels of quality by reducing potential transcription errors and managing the calls in a structured way to obtain as much information as possible with the first contact.”, said Pfizer VP, Rob Goodwin. “Our selection of the Reportum® solution reflects our commitment to streamline our call handling processes with state of the art electronic solutions.”
“We are delighted to announce the SaaS deployment and successful roll-out of the Reportum® solution across Pfizer Safety Call Centre sites for the United States”, said Andrew Rut, CEO at MyMeds&Me. “We believe that Pfizer’s commitment to standardisation on this market-leading, innovative solution underlines the significance of the Reportum® solution to the pharmacovigilance market”.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.
Phase II ALPACA Trial Shows Lepodisiran Produces Significant, Sustained Lipoprotein(a) Reductions
March 31st 2025Eli Lilly’s lepodisiran, an investigational siRNA therapy, achieved significant and durable reductions in lipoprotein(a) levels, a major genetic risk factor for cardiovascular disease.
